Table 1.
Patients’ characteristics at baseline according to the cohorts of prophylaxis against OBI reactivation.
| Variable | Total,n (%) | Pre-emptive cohort, n (%) | 12-month LAM cohort, n (%) | 24-month LAM series, n (%) | P-value |
|---|---|---|---|---|---|
| Time period | Jan 2005-Dec 2011 | Jan 2012-Dec 2017 | Jan 2018-Dec 2020 | ||
| Num. of patients | 187 (100%) | 96 (100%) | 60 (100%) | 31 (100%) | |
| Male sex | 100 (53%) | 52 (54%) | 30 (50%) | 18 (58%) | 0.7 |
| Age, median (range%) |
59 (21-84%) |
63 (53-74%) |
60 (21-74%) |
65 (43-84%) |
0.9 |
| Histological diagnosis: DLBCL |
187 (100%) | 96 (100%) | 60 (100%) | 31 (100%) | |
| Histological subtypes | 0.9 | ||||
| GC | 43 (23%) | 21 (22%) | 14 (23%) | 8 (26%) | |
| N-GC | 25 (13%) | 11 (11%) | 9 (15%) | 5 (12%) | |
| NOS | 119 (64%) | 64 (67%) | 37 (62%) | 18 (58%) | |
| ECOG (PS) 0-2 | 176 (94%) | 92 (96%) | 57 (95%) | 27 (87%) | 1.4 |
| ECOG (PS) 3 | 11 (6%) | 4 (4%) | 3 (5%) | 4 (13%) | 0.9 |
| Ann Arbor stage | 0.37 | ||||
| III | 77 (41%) | 37 (39%) | 29 (48%) | 11 (35%) | |
| IV | 110 (59%) | 59 (61%) | 31 (52%) | 20 (65%) | |
| B Symptoms | 94 (50.5%) | 49 (51%) | 29 (48%) | 16 (52%) | 0.9 |
| Bulky disease | 93 (49.5%) | 51 (53%) | 28 (47%) | 14 (45%) | 0.6 |
| IPI> 3 | 41 (22%) | 21 (22%) | 15 (25%) | 5 (16%) | 0.1 |
| Front line ICHT: R-CHOP-21+2R |
187 (100%) | 96 (100%) | 60 (100%) | 31 (100%) |
Values are n (%) unless otherwise specified.
R-CHOP-21+2R: Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Vincristine and Prednisone (6 cycles of 21 days) and 2 additional Rituximab administration every 21 days (24).
DLBCL, diffuse large B cell lymphoma.
ECOG PS, Eastern Cooperative Group Performance Status.
Ann Arbor staging: stage I defined as one lymph node group; stage II defined as two lymph node groups on one side of the diaphragm; stage III, defined as multiple lymph node groups on both sides of the diaphragm; stage IV, defined as multiple extra-nodal sites or lymph nodes and extra-nodal disease (26).
B symptoms: fever, weight loss >10% in the last 6 months, nocturnal sweat.
Bulky disease: lymph node mass with long axis >5 cm.
IPI: international prognostic index including age greater than 60 years, Ann Arbor stage III or IV, elevated serum LDH, more than 1 extra-nodal site involved (25).